Drug intelligence / Profile preview

CJRB-203

Development stage: Unknown
Lead developer: CJ Bioscience
Modality: Live Biotherapeutic Products → Microbiome Therapeutics

Overview

CJRB-203 is a microbiome-based drug candidate developed by CJ Bioscience for the treatment of Inflammatory Bowel Disease (IBD). It is part of CJ Bioscience's pipeline focusing on gastrointestinal disorders and was in preclinical and early clinical development for this indication.

Beyond the preview

Go deeper on CJRB-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJRB-203.

Explore the full profile